Inspire Medical Systems, Inc.
INSP · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 1.21 | -4.32 | 0.43 |
| FCF Yield | 2.67% | -0.16% | -0.32% | 1.12% |
| EV / EBITDA | 121.60 | 3,457.88 | 3,021.57 | 95.34 |
| Quality | ||||
| ROIC | 1.01% | -0.47% | -0.16% | 4.25% |
| Gross Margin | 85.85% | 84.03% | 84.75% | 84.99% |
| Cash Conversion Ratio | 6.90 | -0.75 | -2.24 | 1.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.68% | 17.86% | 21.68% | 25.32% |
| Free Cash Flow Growth | 1,020.12% | 58.22% | -124.31% | 40.38% |
| Safety | ||||
| Net Debt / EBITDA | -4.66 | -68.02 | -13.06 | -2.09 |
| Interest Coverage | 876.73 | -829.00 | 0.00 | 1,449.27 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.29 | 0.31 | 0.45 |
| Cash Conversion Cycle | 277.09 | 234.82 | 248.29 | 138.55 |